These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20610831)

  • 21. Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
    Goldman MD; Naismith RT
    Neurology; 2015 Mar; 84(9):864-5. PubMed ID: 25636716
    [No Abstract]   [Full Text] [Related]  

  • 22. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naïve T cells, memory T cells and NK cells.
    Vaessen LM; van Besouw NM; Mol WM; Ijzermans JN; Weimar W
    Transpl Immunol; 2006 Apr; 15(4):281-8. PubMed ID: 16635750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
    Henault D; Galleguillos L; Moore C; Johnson T; Bar-Or A; Antel J
    Neurology; 2013 Nov; 81(20):1768-72. PubMed ID: 24132373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
    [No Abstract]   [Full Text] [Related]  

  • 26. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 27. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
    Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
    Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novartis eyes oral MS drug as potential blockbuster.
    Ratner M
    Nat Biotechnol; 2010 Nov; 28(11):1135-6. PubMed ID: 21057464
    [No Abstract]   [Full Text] [Related]  

  • 30. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.
    Ghezzi A; Rocca MA; Baroncini D; Annovazzi P; Zaffaroni M; Minonzio G; Comi G; Filippi M
    J Neurol; 2013 Jan; 260(1):327-9. PubMed ID: 23161460
    [No Abstract]   [Full Text] [Related]  

  • 31. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
    Fujiwara M; Anstadt EJ; Khanna KM; Clark RB
    Clin Immunol; 2015 May; 158(1):103-13. PubMed ID: 25829233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients.
    Boehler T; Schuetz M; Budde K; Neumayer H; Waiser J
    Transplant Proc; 2002 Sep; 34(6):2242-3. PubMed ID: 12270383
    [No Abstract]   [Full Text] [Related]  

  • 37. FTY720: a most promising immunosuppressant modulating immune cell functions.
    Zhang Z; Schluesener HJ
    Mini Rev Med Chem; 2007 Aug; 7(8):845-50. PubMed ID: 17692046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
    Mehling M; Kappos L; Derfuss T
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):492-7. PubMed ID: 21789537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K; Adachi K
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
    Chun J; Brinkmann V
    Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.